Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramosetron in female patients with D-IBS
NCT01736423Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2012
- Primary completion
- May 2014
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ramosetron in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Astellas Pharma. Primary endpoints: Monthly responder rate of global assessment of relief of overall IBS symptoms at 52 weeks, Monthly responder rate of stool form normalization at 52 weeks and 8 more. Started Sep 2012; status: completed.
02
Drugs
ramosetron
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT01736423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736423.